In SCLC, the MEK5–ERK5 axis mediated lipid metabolic reprogramming through regulation of the mevalonate pathway, thereby maintaining tumor cell survival (Cristea et al., 2020). The gene discussed is MAP2K5; the disease is neoplasm.